Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?

Corcept Therapeutics (CORT) reported H1 2025 Korlym sales of $351.6 million, a 13.2% year-over-year increase, yet lowered its full-year 2025 revenue guidance to $850-$900 million from $900-$950 million, underscoring its current revenue concentration risk. The company's long-term growth and diversification strategy centers on its lead pipeline candidate, relacorilant, which has an FDA decision due for Cushing's syndrome by December 30, 2025, and another for platinum-resistant ovarian cancer by July 11, 2026, with management anticipating a patient switch from Korlym upon approval. Successful regulatory outcomes and continued development of relacorilant across multiple oncology indications are crucial for CORT to mitigate its heavy dependence on Korlym and expand its market footprint.

Analysis

Corcept Therapeutics (CORT) presents a high-risk, high-reward investment profile centered on its transition from a single-product company to a more diversified biotech. While its sole-marketed drug, Korlym, generated a 13.2% year-over-year sales increase to $351.6 million in the first half of 2025, this growth is overshadowed by the company's lowered full-year revenue guidance to $850-$900 million from a previous $900-$950 million. This revision, coupled with a prior operational hiccup involving a specialty pharmacy vendor, introduces near-term uncertainty and highlights the significant concentration risk. The company's entire long-term growth thesis rests on its lead pipeline candidate, relacorilant. The investment narrative is dominated by two upcoming, binary regulatory events: an FDA decision on relacorilant for Cushing's syndrome by December 30, 2025, and another for platinum-resistant ovarian cancer by July 11, 2026. A positive outcome for the Cushing's syndrome indication is critical, as management anticipates a full patient switch from Korlym, while an approval in ovarian cancer would represent a significant market expansion. Further studies exploring relacorilant in combination with established therapies like Keytruda and Avastin offer long-term upside but are secondary to the two pivotal FDA decisions.

Key Decisions for Investors

• Investors should recognize that CORT is primarily a catalyst-driven stock, with its valuation heavily dependent on the binary outcomes of the FDA decisions for relacorilant on December 30, 2025, and July 11, 2026.
• The recent downward revision of full-year 2025 revenue guidance is a red flag for operational execution; therefore, investors should closely scrutinize upcoming quarterly reports for Korlym sales trends and management's ability to meet the new, lower targets.
• Positions in CORT carry significant regulatory risk, and any negative news flow or developmental setback regarding the relacorilant program would severely impair the stock's value, making risk management and position sizing critical.
• Consider the company's strategy to switch existing Korlym patients to relacorilant post-approval, which, if successful, could accelerate the new drug's revenue ramp but also makes the initial launch and market adoption a key performance indicator to monitor.